Table of Content


Introduction
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Projects
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones
Appendix



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Products under Development by Companies, 2021 (Contd..7)
Products under Development by Companies, 2021 (Contd..8)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Adienne Pharma & Biotech SA, 2021
Pipeline by Akari Therapeutics Plc, 2021
Pipeline by Alexion Pharmaceuticals Inc, 2021
Pipeline by Alnylam Pharmaceuticals Inc, 2021
Pipeline by Amgen Inc, 2021
Pipeline by Aptarion Biotech AG, 2021
Pipeline by Biocad, 2021
Pipeline by Biosion Inc, 2021
Pipeline by CANbridge Life Sciences Ltd, 2021
Pipeline by Chugai Pharmaceutical Co Ltd, 2021
Pipeline by Generium, 2021
Pipeline by ImmunAbs Inc, 2021
Pipeline by InflaRx NV, 2021
Pipeline by ISU ABXIS Co Ltd, 2021
Pipeline by IVERIC bio Inc, 2021
Pipeline by Navigen Inc, 2021
Pipeline by Novartis AG, 2021
Pipeline by NovelMed Therapeutics Inc, 2021
Pipeline by Prestige BioPharma Ltd, 2021
Pipeline by Ra Pharmaceuticals Inc, 2021
Pipeline by Rallybio Corp, 2021
Pipeline by Regeneron Pharmaceuticals Inc, 2021
Pipeline by Samsung Bioepis Co Ltd, 2021
Pipeline by Staidson (Beijing) Biopharmaceuticals Co Ltd, 2021
Pipeline by Staidson BioPharma Inc, 2021
Pipeline by Tasly Biopharmaceuticals Co Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021